No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,582 | 2,696 | 2,226 | 1,969 | 1,732 | 1,485 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 191 | 147 | 105 | 9 | -147 | 160 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items. In the realm of health and nutrition, Nu Skin provides a comprehensive array of dietary and weight management products. This includes ageLOC Youth, LifePak, and ageLOC Meta nutritional supplements, in addition to ageLOC TR90 programs designed for weight control and body contouring, Beauty Focus Collagen+ skin care supplements, and other related weight management aids. The organization also significantly invests in research and development, particularly for its skincare and nutritional supplement portfolios. Nu Skin operates a network of retail stores and customer service centers exclusively within Mainland China. Its extensive product lines are marketed under its proprietary brands, which include Nu Skin, Pharmanex, and ageLOC. These products reach consumers through multiple sales channels, including direct-to-consumer interactions, an extensive network of independent distributors, and its dedicated e-commerce platform. Nu Skin Enterprises, Inc. was established in 1984 and maintains its corporate headquarters in Provo, Utah.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nu Skin Enterprises, Inc. (NUS)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items. In the realm of health and nutrition, Nu Skin provides a comprehensive array of dietary and weight management products. This includes ageLOC Youth, LifePak, and ageLOC Meta nutritional supplements, in addition to ageLOC TR90 programs designed for weight control and body contouring, Beauty Focus Collagen+ skin care supplements, and other related weight management aids. The organization also significantly invests in research and development, particularly for its skincare and nutritional supplement portfolios. Nu Skin operates a network of retail stores and customer service centers exclusively within Mainland China. Its extensive product lines are marketed under its proprietary brands, which include Nu Skin, Pharmanex, and ageLOC. These products reach consumers through multiple sales channels, including direct-to-consumer interactions, an extensive network of independent distributors, and its dedicated e-commerce platform. Nu Skin Enterprises, Inc. was established in 1984 and maintains its corporate headquarters in Provo, Utah.